<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841724</url>
  </required_header>
  <id_info>
    <org_study_id>BRD 08/9-P</org_study_id>
    <nct_id>NCT00841724</nct_id>
  </id_info>
  <brief_title>Study of a Reduced-toxicity &quot;Submyeloablative&quot; Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies</brief_title>
  <acronym>ITT 08-01</acronym>
  <official_title>Phase II Study of a Reduced-toxicity &quot; Submyeloablative &quot; Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this prospective study is to assess the overall mortality (whether related to
      relapse/progression or toxicity - TRM-) at one year after allogeneic stem cell
      transplantation prepared by a so-called reduced-toxicity &quot;submyeloablative&quot; conditioning
      regimen in patients with hematological malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the overall mortality rate at 12 months after allogeneic stem cell transplantation</measure>
    <time_frame>12 months after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the &quot;classical&quot; criteria (clinical and biological) associated with outcome after allogeneic stem cell transplantation. To evaluate the impact of the modified Charlson comorbidity score (Sorror Score) on TRM and 1-year overall survival</measure>
    <time_frame>12 months after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>Busilvex, Fludara, Thymoglobuline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>D-6: Fludara D-5: Fludara + Busilvex D-4: Fludara + Busilvex D-3: Fludara + Busilvex D-2: Fludara + Thymoglobuline D-1: Thymoglobuline D0: graft infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine, Busulfan, Thymoglobuline</intervention_name>
    <arm_group_label>Busilvex, Fludara, Thymoglobuline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients affiliated to a social security reimbursement system

          -  Adults (men or women) aged between 18 and 65 years

          -  Negative test for pregnancy

          -  ECOG 0-1 or Karnofsky Index ≥ 70%

          -  Availability of an HLA-identical sibling donor, or an HLA-matched unrelated donor
             (10/10 HLA compatibility in A, B, C, DRB1, DQB1 (a single allelic mismatch at the
             level of Cw can be accepted)

          -  Life expectancy &gt; 6 months

          -  Signed informed consent

          -  Diagnosis of an hematological malignancy that is considered to be eligible for an
             allogeneic stem cell transplantation

        Exclusion Criteria:

          -  Pregnant woman or not willing to take effective contraception

          -  Classical contra-indications to the allogeneic stem cell transplantation procedure

          -  Any contra-indication to the use of the drugs contained within the conditioning
             regimen according to the summary of product characteristics

          -  Patients aged &lt; 50 years and deemed to be eligible for a &quot;standard&quot; or conventional
             myeloablative conditioning regimen

          -  An HLA-matched sibling donor who has a contra-indication for stem cell mobilization
             and collection

          -  History of uncontrolled psychiatric condition

          -  Patients who have participated to another trial testing an experimental drug within
             one month prior to inclusion in this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad Mohty, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nantes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <name_title>Anne Omnès</name_title>
    <organization>Nantes University Hospital</organization>
  </responsible_party>
  <keyword>Allogeneic stem cell transplantation</keyword>
  <keyword>Reduced-intensity conditioning</keyword>
  <keyword>Reduced-toxicity conditioning</keyword>
  <keyword>Hematological malignancies</keyword>
  <keyword>IV Busulfan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

